Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7434.

https://doi.org/10.1182/blood-2023-188683

Published: 2023

Journal Articles

Exploring Symptom Burden, Treatment Bother, Physical Function, and Quality of Life By Frailty Status in Patients with Multiple Myeloma

Nicholas C Coombs, Emily Beamon, Emelly Rusli, Debra Wujcik, Aaron Galaznik, Omer Jamy

Blood (2023) 142 (Supplement 1): 7283.

https://doi.org/10.1182/blood-2023-180943

Published: 2023

Journal Articles

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Blood (2023) 142 (Supplement 1): 897.

https://doi.org/10.1182/blood-2023-187859

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

Low-Dose Decitabine Plus Venetoclax As Post-Transplant Maintenance for High-Risk Myeloid Malignancies

Katherine Parks, Kendall Diebold, Donna Salzman, Antonio Di Stasi, Manuel Espinoza-Gutarra, Ravi Bhatia, Zaid Al-Kadhimi, Omer Jamy

Blood (2023) 142 (Supplement 1): 7052.

https://doi.org/10.1182/blood-2023-184658

Published: 2023

Journal Articles

Addition of Single Dose Gemtuzumab Ozogamicin to Intensive Induction Chemotherapy in Core-Binding Factor Acute Myeloid Leukemia

Garrett Bourne, Kendall Diebold, Manuel Espinoza-Gutarra, Zaid Al-Kadhimi, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Ravi Bhatia, Omer Jamy

Blood (2023) 142 (Supplement 1): 5848.

https://doi.org/10.1182/blood-2023-189853

Published: 2023

Journal Articles

Exploring Symptom Burden, Treatment Bother, Physical Function, and Quality of Life By Frailty Status in Patients with Acute Myeloid Leukemia

Nicholas C Coombs, Emily Beamon, Emelly Rusli, Debra Wujcik, Aaron Galaznik, Omer Jamy

Blood (2023) 142 (Supplement 1): 5105.

https://doi.org/10.1182/blood-2023-180887

Published: 2023

Journal Articles

Real-World Evidence of Treatment-Free Remission in Chronic Myeloid Leukemia at an Academic Center in the Deep South

Greg Bascug, Garrett Bourne, Kendall Diebold, Joshua Knapp, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Ravi Bhatia, Omer Jamy

Blood (2023) 142 (Supplement 1): 7425.

https://doi.org/10.1182/blood-2023-184757

Published: 2023

Journal Articles

Idarubicin and Cytarabine with and without Midostaurin for FLT3-Mutated Acute Myeloid Leukemia

Kendall Diebold, Sarah Worth, Kimo Bachiashvili, Pankit Vachhani, Sravanti Rangaraju, Manuel Espinoza-Gutarra, Zaid Al-Kadhimi, Ravi Bhatia, Omer Jamy

Blood (2023) 142 (Supplement 1): 5910.

https://doi.org/10.1182/blood-2023-185198

Published: 2023

Journal Articles

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

Blood (2023) 142 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2023-187744

Published: 2023

Journal Articles

Novel developments in the prophylaxis and treatment of acute GVHD

Omer Jamy, Robert Zeiser, Yi-Bin Chen

Blood (2023) 142 (12): 1037–1046.

https://doi.org/10.1182/blood.2023020073

Published: 2023

Journal Articles

Risk of Mortality and Leukemic Transformation in Primary Myelofibrosis before and after Ruxolitinib Approval

John William Thomas, Mithun Vinod Shah, MD PhD, Pankit Vachhani, MD, Omer Jamy, MD, Ronald S. Go, MD, Gaurav Goyal, MD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-134161

Published: 2020

Journal Articles

Genomic Landscape of Sex Disparities in Multiple Myeloma

Susan Bal, MDMBBS, Kwangmin Choi, PhD, Omer Jamy, MD, Saulius K. Girnius, MD, Heather J Landau, MD, Luciano J. Costa, MD PhD

Blood (2019) 134 (Supplement_1): 3067.

https://doi.org/10.1182/blood-2019-127429

Published: 2019

Journal Articles

A Phase II Clinical Trial of Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prevention Following Myeloablative Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Omer Jamy, MD, Racquel Innis-Shelton, MD, Susan Bal, MDMBBS, Ravi K. Paluri, MD, Samina Karim, Joseph H. Chewning, MD, Donna Salzman, MD, Luciano J. Costa, MD PhD, Antonio Di Stasi, MD, Lawrence S. Lamb, Jr., PhD, Shin Mineishi, Ayman Saad, MD

Blood (2019) 134 (Supplement_1): 2003.

https://doi.org/10.1182/blood-2019-129536

Published: 2019

Journal Articles

Temporal Trends in Early Mortality in Acute Promyelocytic Leukemia in the United States

Ana C. Xavier, MD, Matthew A. Kutny, MD, Omer Jamy, MD, Luciano J Costa, MD PhD

Blood (2018) 132 (Supplement 1): 710.

https://doi.org/10.1182/blood-2018-99-114171

Published: 2018

Journal Articles

Outcomes of Acute Myeloid Leukemia Patients with Indeterminate Day 14 Bone Marrow Results Treated with and without Re-Induction Chemotherapy

Omer Jamy, MD, Charles Bodine, MD, Rehan Sarmad, MD MBBS, Awal Chadha, MBBS, Pankit Vachhani, MD, Luciano J Costa, MD PhD, Ayman Saad, MD, Nikolaos Papadantonakis, MDPhD MSc, Harry P. Erba, MD PhD, Antonio Di Stasi, MD

Blood (2018) 132 (Supplement 1): 2688.

https://doi.org/10.1182/blood-2018-99-114090

Published: 2018

Journal Articles

Impact of Insurance Status on Survival of Patients Diagnosed with Acute Promyelocytic Leukemia in the United States

Omer Jamy, MD, Ana C. Xavier, MD, Luciano J Costa, MD PhD

Blood (2018) 132 (Supplement 1): 321.

https://doi.org/10.1182/blood-2018-99-116125

Published: 2018

Journal Articles

Risk and Outcomes of Second Malignant Neoplasms in Chronic Myeloid Leukemia Survivors

Omer Jamy, Rehan Sarmad, MD MBBS, Luciano J. Costa, MD PhD

Blood (2017) 130 (Supplement 1): 350.

https://doi.org/10.1182/blood.V130.Suppl_1.350.350

Published: 2017

Journal Articles

Favorable Outcomes with Fludarabine, High Dose Cytarabine and Granulocyte Colony Stimulating Factor (FLAG) As Re-Induction for Residual Acute Myeloid Leukemia on Day 14 Bone Marrow

Omer Jamy, Sejong Bae, Luciano J. Costa, MD PhD, Harry P. Erba, MD PhD, Nikolaos Papadantonakis, MD MSc

Blood (2017) 130 (Supplement 1): 3871.

https://doi.org/10.1182/blood.V130.Suppl_1.3871.3871

Published: 2017

Journal Articles

Survival of Chronic Myeloid Leukemia Patients in Comparison to General Population in the Tyrosine Kinase Inhibitors Era: A US Population Based Study

Rehan Sarmad, MD MBBS, Omer Jamy, Luciano J. Costa, MD PhD

Blood (2017) 130 (Supplement 1): 2165.

https://doi.org/10.1182/blood.V130.Suppl_1.2165.2165

Published: 2017

NARROW

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Exploring Symptom Burden, Treatment Bother, Physical Function, and Quality of Life By Frailty Status in Patients with Multiple Myeloma

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Low-Dose Decitabine Plus Venetoclax As Post-Transplant Maintenance for High-Risk Myeloid Malignancies

Addition of Single Dose Gemtuzumab Ozogamicin to Intensive Induction Chemotherapy in Core-Binding Factor Acute Myeloid Leukemia

Exploring Symptom Burden, Treatment Bother, Physical Function, and Quality of Life By Frailty Status in Patients with Acute Myeloid Leukemia

Real-World Evidence of Treatment-Free Remission in Chronic Myeloid Leukemia at an Academic Center in the Deep South

Idarubicin and Cytarabine with and without Midostaurin for FLT3-Mutated Acute Myeloid Leukemia

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

Novel developments in the prophylaxis and treatment of acute GVHD

Risk of Mortality and Leukemic Transformation in Primary Myelofibrosis before and after Ruxolitinib Approval

Genomic Landscape of Sex Disparities in Multiple Myeloma

A Phase II Clinical Trial of Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prevention Following Myeloablative Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation

Temporal Trends in Early Mortality in Acute Promyelocytic Leukemia in the United States

Outcomes of Acute Myeloid Leukemia Patients with Indeterminate Day 14 Bone Marrow Results Treated with and without Re-Induction Chemotherapy

Impact of Insurance Status on Survival of Patients Diagnosed with Acute Promyelocytic Leukemia in the United States

Risk and Outcomes of Second Malignant Neoplasms in Chronic Myeloid Leukemia Survivors

Favorable Outcomes with Fludarabine, High Dose Cytarabine and Granulocyte Colony Stimulating Factor (FLAG) As Re-Induction for Residual Acute Myeloid Leukemia on Day 14 Bone Marrow

Survival of Chronic Myeloid Leukemia Patients in Comparison to General Population in the Tyrosine Kinase Inhibitors Era: A US Population Based Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only